Serum globotriaosylceramide assay as a screening test for Fabry disease in patients with ESRD on maintenance dialysis in Korea

Korean Journal of Internal Medicine

Volumn 25, Issue 4, 2010, Pages 415-421

  Kim, Jeong Yup ^a   Hyun, Young Youl ^a   Lee, Ji Eun ^b   Yoon, Hye Ran ^c   Kim, Gu Hwan ^d   Yoo, Han Wook ^e   Cho, Seong Tae ^f   Chun, No Won ^f   Jeoung, Byoung Chunn ^f   Kim, Hwa Jung ^f   Kim, Keong Wook ^f   Kim, Seong Nam ^f   Kim, Yung A ^f   Lee, Hyun Ah ^f   Lee, Jong Young ^f   Lee, Yung Chun ^f   Lim, Hun Kwan ^f   Oh, Keong Sik ^f   Son, Seong Hwan ^f   Yu, Beong Hee ^f   Wee, Kyeong So ^f   Lee, Eun Jong ^f   Lee, Young Ki ^g   Noh, Jung Woo ^g   Kim, Seung Jung ^h   Choi, Kyu Bok ^h   Yu, Suk Hee ⁱ   Pyo, Heui Jung ^a   Kwon, Young Joo ^a   more..

^a Korea University College of Medicine   (South Korea)

^b Wonkwang University   (South Korea)

^c Duksung Women's University   (South Korea)

^d Asan Medical Center   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Western Dialysis Physician Association (WDPA)   (South Korea)

^g Hallym University College of Medicine   (South Korea)

^h Ewha Womans University School of Medicine   (South Korea)

ⁱ Chung Ang University College of Medicine   (South Korea)

Author keywords

End stage renal disease; Fabry disease; Globotriaosylceramide

Indexed keywords

ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE;

ADULT; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FABRY DISEASE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KOREA; MAINTENANCE THERAPY; MALE; MUTATIONAL ANALYSIS; PATIENT ASSESSMENT; PROTEIN BLOOD LEVEL; SCREENING TEST; TANDEM MASS SPECTROMETRY;

ADULT; AGED; ALPHA-GALACTOSIDASE; FABRY DISEASE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TRIHEXOSYLCERAMIDES;

EID: 78650971082     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2010.25.4.415     Document Type: Article

References (23)

1. Bekri S, Enica A, Ghafari T, et al. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Nephron Clin Pract 2005;101:c33-c38.
2. Rodriguez-Mari A, Coll MJ, Chabas A. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum Mutat 2003;22:258.
3. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-242.
4. Linthorst GE, Hollak CE, Korevaar JC, Van Manen JG, Aerts JM, Boeschoten EW. alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant 2003;18:1581-1584.
5. Kotanko P, Kramar R, Devrnja D, et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004;15:1323-1329.
6. Tsakiris D, Simpson HK, Jones EH, et al. Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 1996;11 Suppl 7:4-20.
7. Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002;61:249-255.
8. Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a renal variant phenotype. Kidney Int 2003;64:801-807
9. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-293.
10. Meroni M, Spisni C, Tazzari S, et al. Isolated glomerular proteinuria as the only clinical manifestation of Fabry's disease in an adult male. Nephrol Dial Transplant 1997;12:221-223.
11. Brenner BM, Grünfeld JP. Renoprotection by enzyme replacement therapy. Curr Opin Nephrol Hypertens 2004;13:231-241.
12. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under- recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-346.
13. Choi JH, Cho YM, Suh KS, et al. Short-term efficacy of enzyme replacement therapy in Korean patients with Fabry disease. J Korean Med Sci 2008;23:243-250.
14. Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007;30:184-192.
15. Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004;144(5 Suppl):S20-S26.
16. Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, Meikle PJ. Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease. Clin Chem 2004;50:1979-1985.
17. Ginzburg L, Kacher Y, Futerman AH. The pathogenesis of glycosphingolipid storage disorders. Semin Cell Dev Biol 2004;15:417-431.
18. Pastores GM, Lien YH. Biochemical and molecular genetic basis of Fabry disease. J Am Soc Nephrol 2002;13 Suppl 2:S130-133.
19. Nelson BC, Roddy T, Araghi S, et al. Globotriaosylceramide isoform profiles in human plasma by liquid chromatography- tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004;805:127-134.
20. Mills K, Johnson A, Winchester B. Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry. FEBS Lett 2002;515: 171-176.
21. Young E, Mills K, Morris P, et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 2005;94: 51-54.
22. Yoon HR, Cho K, Yoo HW, et al. Determination of plasma C16-C24 globotriaosylceramide (Gb3) isoforms by tandem mass spectrometry for diagnosis of Fabry disease. J Genet Med 2007;4:45-52.
23. Forni S, Fu X, Schiffmann R, Sweetman L. Falsely elevated urinary Gb3 (globotriaosylceramide, CTH, GL3). Mol Genet Metab 2009;97:91.